Stay updated on KITE-585 in Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the KITE-585 in Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the KITE-585 in Multiple Myeloma Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:35:18.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the safety and tolerability evaluation of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting B-cell maturation antigen (BCMA) in participants with relapsed/refractory multiple myeloma.
    Difference
    0.1%
    Check dated 2024-06-06T14:41:27.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the health conditions and prior treatments required for inclusion in the study. This change provides more specific information about the requirements for participation in the clinical trial.
    Difference
    19%
    Check dated 2024-05-22T21:12:25.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:47:06.000Z thumbnail image

Stay in the know with updates to KITE-585 in Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the KITE-585 in Multiple Myeloma Clinical Trial page.